Therapy with combined MET/MEK inhibition decreases anti-RTK antibody accumulation in tumors from RCC PDXs, suggesting that a decrease in the plasma membrane levels of MET, EGFR, and HER2 corresponds to therapeutic benefit. Here, MET is linked to renal cell carcinoma.